COMPLEMENT-DEPENDENT PROSTAGLANDIN SYNTHESIS IN SEPSIS
脓毒症中补体依赖性前列腺素合成
基本信息
- 批准号:3466035
- 负责人:
- 金额:$ 9.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1987
- 资助国家:美国
- 起止时间:1987-04-01 至 1992-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Although low systemic vascular resistance is a consistent
hemodynamic feature of sepsis in humans, relatively little is
known about the mechanisms involved. The problem is important,
however, because defective regulation of peripheral vasomotor
tone is a contributing factor leading to the development of
systemic arterial hypotension (i.e., septic shock) in patients with
overwhelming infections. Shock remains the single most
important predictor of mortality in septic patients. The purpose
of this study is to test the hypothesis that decreased vasomotor
tone in sepsis is mediated (at least in part) by vasodilating
prostaglandins (PGE2 and/or PGI2) and that release of these
substances is initiated by activation of the complement system.
The studies will employ a rabbit model of endotoxemia that is
characterized by low systemic vascular resistance and high
cardiac output; i.e., the model satisfactorily replicates the
systemic hemodynamic profile of human sepsis. Cardiac output
will be measured by thermodilution; regional blood flow will be
assessed using radioactive microspheres; plasma levels of
metabolites of PGE2 and PGI2 will be determined by
radioimmunoassay. Three series of experiments will be
conducted. The first will examine the effect of
pharmacologically limiting the formation of prostaglandins or
complement-derived peptides on systemic and regional
hemodynamics and plasma prostaglandin levels in endotoxic
rabbits. Prostaglandin synthesis will be inhibited by administering
meclofenamate or ibuprofen; formation of complement-derived
peptides will be inhibited by prior decomplementation with cobra
venom factor or treatment with inhibitors of complement
activation. The second series of experiments will investigate
systemic and regional hemodynamics and plasma prostaglandin
levels in rabbits infused with graded doses of either zymosan-
activated plasma (a source of complement-derived peptides) or
cobra venom factor (to initiate the formation of these peptides in
vivo). The studies will be performed in the presence and absence
of PG synthesis inhibitors. The third series of experiments will
ascertain whether the hemodynamic effects of vasodilating doses
of endotoxin or activated complement depend upon interaction
with polymorphonuclear leukocytes. These studies should provide
important new insights into the mechanisms underlying the
derangements in vasomotor tone in sepsis and possibly lead to
improved therapeutic strategies.
尽管低的全身血管阻力是一致的
脓毒症的血液动力学特征在人类中相对较少
了解其中涉及的机制。这个问题很重要,
然而,由于外周血管运动调节的缺陷
语气是导致发展的一个促成因素
慢性阻塞性肺疾病患者的全身动脉低血压(即感染性休克)
压倒性的感染。最令人震惊的仍然是
败血症患者死亡率的重要预测因子。目的
这项研究的目的是检验这样一种假设,即血管运动减少
脓毒症的紧张感(至少部分)是通过血管扩张来调节的。
前列腺素(PGE2和/或PGI2)及其释放
物质是通过激活补体系统来启动的。
这项研究将使用内毒素血症的兔模型
以低血管阻力和高血管阻力为特征
心输出量;即,该模型令人满意地复制了
人类脓毒症的全身血流动力学特征。心输出量
将通过热稀释来测量;局部血流量将
使用放射性微球进行评估;血浆中
前列腺素E_2和前列环素的代谢物将通过
放射免疫分析。三个系列的实验将是
指挥。首先,我们将考察
从药理上限制前列腺素或
补体衍生多肽对全身和局部的影响
内毒素血症患者血流动力学及血浆前列腺素水平的变化
兔子。前列腺素的合成将被抑制
甲氯芬酯或布洛芬;补体衍生的形成
多肽将被预先用眼镜蛇分解而被抑制
毒液因子或补体抑制剂治疗
激活。第二系列实验将研究
全身和局部血流动力学与血浆前列腺素
注射不同剂量酵母多糖的兔体内水平
激活的血浆(补体衍生多肽的来源)或
眼镜蛇毒液因子(启动这些多肽的形成
Vivo)。研究将在在场和不在场的情况下进行
PG合成抑制剂。第三系列实验将
确定血管扩张剂量对血流动力学的影响
内毒素或激活的补体取决于相互作用
有多形核白细胞。这些研究应该提供
对潜在机制的重要新见解
脓毒症患者血管舒缩张力紊乱并可能导致
改进治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mitchell P. Fink其他文献
Effects of nonsteroidal anti-inflammatory drugs on renal function in septic dogs.
非甾体抗炎药对脓毒症犬肾功能的影响。
- DOI:
10.1016/0022-4804(84)90135-5 - 发表时间:
1984 - 期刊:
- 影响因子:0
- 作者:
Mitchell P. Fink;Thomas J. MacVittie;Larry C. Casey - 通讯作者:
Larry C. Casey
Postoperative complications in patients with disabling psychiatric illnesses or intellectual handicaps. A case-controlled, retrospective analysis.
患有致残性精神疾病或智力障碍的患者的术后并发症。
- DOI:
10.1001/archsurg.1990.01410230030005 - 发表时间:
1990 - 期刊:
- 影响因子:0
- 作者:
B. Cutler;Mitchell P. Fink - 通讯作者:
Mitchell P. Fink
Biology of heterotrimeric G-protein signaling.
异源三聚体 G 蛋白信号传导生物学。
- DOI:
- 发表时间:
2000 - 期刊:
- 影响因子:8.8
- 作者:
R. Forse;John M. Luce;Michael B. Yaffe;Mitchell P. Fink - 通讯作者:
Mitchell P. Fink
Hemorrhagic Ascites: An Unusual Presentation of Primary Splenic Lymphoma
- DOI:
10.1016/s0016-5085(82)80346-6 - 发表时间:
1982-08-01 - 期刊:
- 影响因子:
- 作者:
Joseph F. Hacker;Joel E. Richter;Robert S. Pyatt;Mitchell P. Fink - 通讯作者:
Mitchell P. Fink
CRISIS IN CRITICAL CARE The Demand for Critical Care Services is Increasing Critical care
重症监护危机 对重症监护服务的需求正在增加 重症监护
- DOI:
- 发表时间:
2005 - 期刊:
- 影响因子:0
- 作者:
David T. Huang;T. Osborn;K. Gunnerson;Scott R. Gunn;Stephen Trzeciak;Edward Kimball;Mitchell P. Fink;De Angus;R. Dellinger;Emanuel P. Rivers - 通讯作者:
Emanuel P. Rivers
Mitchell P. Fink的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mitchell P. Fink', 18)}}的其他基金
MOLECULAR BASIS FOR EPITHELIAL BARRIER DYSFUNCTION/PROJECT 2
上皮屏障功能障碍的分子基础/项目 2
- 批准号:
6829217 - 财政年份:2004
- 资助金额:
$ 9.74万 - 项目类别:
COMPLEMENT-DEPENDENT PROSTAGLANDIN SYNTHESIS IN SEPSIS
脓毒症中补体依赖性前列腺素合成
- 批准号:
3466038 - 财政年份:1987
- 资助金额:
$ 9.74万 - 项目类别:
COMPLEMENT-DEPENDENT PROSTAGLANDIN SYNTHESIS IN SEPSIS
脓毒症中补体依赖性前列腺素合成
- 批准号:
3466034 - 财政年份:1987
- 资助金额:
$ 9.74万 - 项目类别:
相似海外基金
Complement inhibitors targeted to the ischemic brain for the treatment of stroke
针对缺血性大脑的补体抑制剂用于治疗中风
- 批准号:
9316844 - 财政年份:2017
- 资助金额:
$ 9.74万 - 项目类别:
Role of complement factor MASP-1/3 in age-related macular degeneration and therapeutic effect of novel complement inhibitors
补体因子MASP-1/3在年龄相关性黄斑变性中的作用及新型补体抑制剂的治疗效果
- 批准号:
17K16975 - 财政年份:2017
- 资助金额:
$ 9.74万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Complement inhibitors for treatment of chronic inflammatory diseases
用于治疗慢性炎症性疾病的补体抑制剂
- 批准号:
nhmrc : 1082090 - 财政年份:2015
- 资助金额:
$ 9.74万 - 项目类别:
Project Grants
Complement inhibitors for treatment of chronic inflammatory diseases
用于治疗慢性炎症性疾病的补体抑制剂
- 批准号:
nhmrc : GNT1082090 - 财政年份:2015
- 资助金额:
$ 9.74万 - 项目类别:
Project Grants
Scabies mite complement inhibitors as targets for novel therapeutics
疥螨补体抑制剂作为新疗法的靶点
- 批准号:
nhmrc : 1054968 - 财政年份:2013
- 资助金额:
$ 9.74万 - 项目类别:
Early Career Fellowships
N. Meningitidis-inspired stealthiness: Prolonging the circulation times of anticancer nanocarriers by scavenging endogenous complement-inhibitors.
脑膜炎奈瑟氏球菌启发的隐秘性:通过清除内源性补体抑制剂来延长抗癌纳米载体的循环时间。
- 批准号:
214146 - 财政年份:2010
- 资助金额:
$ 9.74万 - 项目类别:
Fellowship Programs














{{item.name}}会员




